Wednesday, January 9, 2019 at 3pm: SHARP WIP
Jordan Cloyd, MD
Wednesday, January 9, 2019 at 4pm: SHARP Faculty Meeting
SHARP Faculty Roundtable
Upcoming Presentations:
1/16/2019 – Carmen Quatman, MD, PhD, SHARP WIP
1/16/2019 – Azeem Malik, MBBS, SHARP Journal Club
1/23/2019 – Scott Strassels, Pharm D, PhD, SHARP WIP
1/30/2019 – Amy Rushing, MD, SHARP WIP
NEWS:
Below are several funding opportunities in cancer research. At the end of this message, there is a link to the OSU limited submission opportunities as well.
NCI Requests for Applications
HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional)
(RFA-AT-19-004)
National Cancer Institute
Application Receipt Date(s): February 08, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)
(RFA-EB-18-003)
National Cancer Institute
Application Receipt Date(s): March 22, 2019, June 20, 2019, October 22, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 22, 2021 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)
(RFA-NS-19-016)
National Cancer Institute
Application Receipt Date(s): January 9, 2019, March 22, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)
(RFA-NS-19-017)
National Cancer Institute
Application Receipt Date(s): January 9, 2019; March 22, 2019; June 21, 2019; October 21, 2019; February 21, 2020; June 22, 2020; October 21, 2020; February 21, 2021, by 5:00 PM local time of applicant organization.
HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)
(RFA-NS-19-018)
National Cancer Institute
Application Receipt Date(s): January 9, 2019, March 22, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020, February 21, 2021, by 5:00 PM local time of applicant organization.
HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain – (U44 Clinical Trial Not Allowed)
(RFA-NS-19-020)
National Cancer Institute
Application Receipt Date(s): January 9, 2019 and March 6, 2019, by 5:00PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
(RFA-NS-19-021)
National Cancer Institute
Application Receipt Date(s): February 1, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
HEAL Initiative: Early Phase Pain Investigation Clinical Network – Clinical Coordinating Center (U24 Clinical Trial Not Allowed
(RFA-NS-19-023)
National Cancer Institute
Application Receipt Date(s): February 6, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
HEAL Initiative: Early Phase Pain Investigation Clinical Network – Data Coordinating Center (U24 Clinical Trials Not Allowed)
(RFA-NS-19-024)
National Cancer Institute
Application Receipt Date(s): February 6, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
HEAL Initiative: Early Phase Pain Investigation Clinical Network – Specialized Clinical Centers (U24 Clinical Trial Not Allowed)
(RFA-NS-19-025)
National Cancer Institute
Application Receipt Date(s): February 6, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trial Not Allowed)
(RFA-OD-19-012)
National Cancer Institute
Application Receipt Date(s): January 24, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)
(RFA-CA-19-029)
National Cancer Institute
Application Receipt Date(s): February 26, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)
(RFA-CA-19-030)
National Cancer Institute
Application Receipt Date(s): February 26, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NIH Research Evaluation and Commercialization Hubs (REACH) Awards (U01 Clinical Trial Not Allowed)
(RFA-OD-19-014)
National Cancer Institute
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt Date(s): March 19, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date
NCI Program Announcements
Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)
(PAR-19-098)
National Cancer Institute
Application Receipt/Submission Date(s): November 7, 2019 and November 4, 2020 by 5:00 PM local time of the applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01 Clinical Trial Optional)
(PAR-19-101)
National Cancer Institute
Application Receipt/Submission Date(s): January 30, 2019; July 30, 2019; January 30, 2020; July 30, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)
(PAR-19-093)
National Cancer Institute
Application Receipt/Submission Date(s): March 4, 2019, March 4, 2020, March 4, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)
(PA-19-111)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)
(PA-19-112)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required)
(PA-19-116)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
(PA-19-117)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NIH Pathway to Independence Award (Parent K99/R00 – Independent Clinical Trial Required)
(PA-19-129)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
NIH Pathway to Independence Award (Parent K99/R00 – Independent Clinical Trial Not Allowed)
(PA-19-130)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
(PAR-19-113)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 – Clinical Trial Required)
(PAR-19-133)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 25, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
(PAR-19-134)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 25, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)
(PAR-19-135)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 25, 2019 Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)
(PAR-19-136)
National Cancer Institute
Application Receipt/Submission Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is February 5, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Limited submission funding and prize opportunities are available online.
New Funding Opportunity – CCTS 2019 Pilot Research Grant
The Ohio State University Center for Clinical and Translational Science (CCTS) is inviting applications for Pilot Research Grants which align with our 6th Annual CCTS Scientific Meeting titled, “Teaming Up on Science for a Healthier Ohio”.
The Pilot Translational and Clinical Studies Program of the CCTS is releasing this RFA specially to align with the 2017-2019 State Health Improvement Plan (SHIP), a strategic menu of priorities, outcome objectives and evidence-based strategies designed to address three of Ohio’s greatest health challenges and priority topics:
1) Mental health and addiction,
2) Chronic disease and
3) Maternal and infant health.
The CCTS invites novel proposals of pilot clinical and translational studies by multidisciplinary teams to address any of the three health priorities of Ohio. Closing Ohio’s health gaps will require comprehensive, multidisciplinary or team science approaches that may involve public- and private sector stakeholder collaboration. With the Teaming Up on Science for a Healthier Ohio Pilot Grant, the CCTS will fund meritorious scientific projects that aim to close Ohio’s troubling health gaps and ensure that every Ohioan has the same opportunity for a healthy life. Budgets up to $25,000 will be considered. All pilot projects must be completed within one year and lead to new knowledge to enhance human health and behavior, lengthen life, and reduce illness, disability and health disparities in the State of Ohio.
Learn More
New Grant Awards
Send us news of your grant successes! Email to Lori Bardon (lori.bardon@osumc.edu).
Publications and other Scholarly Successes
Daniel, V.T., Ingraham, A.M., Khubchandani, J.A., Ayturk, D, Kiefe, C.I., Santry, H.P. Variations in the Delivery of Emergency General Surgery Care in the Era of Acute Care Surgery. The Joint Commission Journal on Quality and Patient Safety, vol.45, no. 1, 2019, pp. 14-23.
Schneeberger, S., Phillips, S., Huang, L.-C., Pierce, R.A., Etemad, S.A., Poulose, B.K. Cost-Utility Analysis of Biologic and Biosynthetic Mesh in Ventral Hernia Repair: When Are They Worth It? 2019. Journal of the American College of Surgeons, 228(1), pp. 66-71.
Palmer Kelly, E., Agne, J.L., Hyer, M., Meara, A., Olsen, G., Pawlik, T.M. A systematic review of the methods utilised to measure the relationship between cancer patients and oncologists: Implications for future research and practice. 2018. European Journal of Cancer Care, art.no. e12981, Article in Press.
Mallow, P.J., Belk, K.W., Topmiller, M., Strassels, S.A. Geographic variation in hospital costs, payments, and length of stay for opioid-related hospital visits in the USA. 2018. Journal of Pain Research, 11, pp. 3079-3088.
Guzman-Pruneda, F.A., Husain, S.G., Jones, C.D., Beal, E.W., Porter, E., Grove, M., Moffatt-Bruce, S., Schmidt, C.R. Compliance with preoperative care measures reduces surgical site infection after colorectal operation. 2018. Journal of Surgical Oncology, Article in Press.
Daniel, V.T., Ayturk, D., Ward, D.V., McCormick, B.A., Santry, H.P. The influence of payor status on outcomes associated with surgical repair of upper gastrointestinal perforations due to peptic ulcer disease in the United States. 2019. American Journal of Surgery, 2017 (1), pp.121-125.
Daniel, V.T., Ayturk, D., Kiefe, C.I., Santry, H.P. The current state of the acute care surgery workforce: A boots on the ground perspective. 2018. American Journal of Surgery, 216(6), pp.1076-1081.
We pull publication data from Scopus, based on our ORCID list. If you have other publications (i.e. book chapters), or invited lectures, patents, etc. please send to Lori Bardon (lori.bardon@osumc.edu) for inclusion on this list!
ABSTRACT DEADLINES
Send us the names of your favorite meetings! Email to Lori Bardon (lori.bardon@osumc.edu).
DIRECTOR’s OFFICE HOURS:
Dr. Strassels’ office hours are every Wednesday from 8:00AM-11:00AM. Contact Lori Bardon (lori.bardon@osumc.edu) to schedule a 30 minute block of one on one time with the SHARP Scientific Director.
Wednesday, January 30, 2019 at 3pm: SHARP WIP 
